These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 28488978)
1. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report. Chong I; Chao A Perm J; 2017; 21():16-060. PubMed ID: 28488978 [TBL] [Abstract][Full Text] [Related]
2. Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept. Gavigan GM; Kanigsberg ND; Ramien ML J Cutan Med Surg; 2018; 22(5):514-515. PubMed ID: 29421925 [TBL] [Abstract][Full Text] [Related]
3. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Schneider JA; Cohen PR Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852 [TBL] [Abstract][Full Text] [Related]
4. Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Case Report and Literature Review. Meledathu S; Gordon M; Thornton M; Ashinoff R J Drugs Dermatol; 2023 Nov; 22(11):e24-e28. PubMed ID: 37943271 [TBL] [Abstract][Full Text] [Related]
5. Pediatric SJS/TEN Subdued by a Combination of Dexamethasone, Cyclosporine, and Etanercept. Coulombe J; Belzile E; Duhamel A; Rault P; Buteau C; DeBruycker JJ; Bussières JF J Cutan Med Surg; 2019; 23(5):547-550. PubMed ID: 31478770 [TBL] [Abstract][Full Text] [Related]
6. The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential. So N; Leavitt E; Aleshin M; Worswick S Dermatol Ther; 2018 Sep; 31(5):e12684. PubMed ID: 30175438 [TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of Efficacy and Safety of Monotherapy and Combination Therapy With Biologic for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Sachdeva M; Maliyar K; Ponzo MG J Cutan Med Surg; 2021; 25(6):598-615. PubMed ID: 33631950 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. Gilbert M; Scherrer LA Dermatol Ther; 2019 Jan; 32(1):e12758. PubMed ID: 30285308 [TBL] [Abstract][Full Text] [Related]
9. Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. Wang R; Zhong S; Tu P; Li R; Wang M Dermatol Ther; 2019 Jul; 32(4):e12832. PubMed ID: 30659711 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review. Wang F; Gao X; Chen X; Tang X; Chen H; Han J J Dermatol; 2019 Nov; 46(11):1035-1038. PubMed ID: 31436331 [TBL] [Abstract][Full Text] [Related]
11. Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis. Sato S; Kanbe T; Tamaki Z; Furuichi M; Uejima Y; Suganuma E; Takano T; Kawano Y Pediatr Int; 2018 Aug; 60(8):697-702. PubMed ID: 29888432 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. Pham CH; Gillenwater TJ; Nagengast E; McCullough MC; Peng DH; Garner WL Burns; 2019 Nov; 45(7):1634-1638. PubMed ID: 31466921 [TBL] [Abstract][Full Text] [Related]
13. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. Zhang S; Tang S; Li S; Pan Y; Ding Y J Dermatolog Treat; 2020 Feb; 31(1):66-73. PubMed ID: 30702955 [No Abstract] [Full Text] [Related]
14. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. Kirchhof MG; Miliszewski MA; Sikora S; Papp A; Dutz JP J Am Acad Dermatol; 2014 Nov; 71(5):941-7. PubMed ID: 25087214 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Dreyer SD; Torres J; Stoddard M; Leavitt E; Sutton A; Aleshin M; Crew A; Worswick S Cutis; 2021 Jun; 107(6):E22-E28. PubMed ID: 34314327 [TBL] [Abstract][Full Text] [Related]
16. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. Lin CC; Chen CB; Wang CW; Hung SI; Chung WH Expert Rev Clin Immunol; 2020 Apr; 16(4):373-387. PubMed ID: 32154748 [No Abstract] [Full Text] [Related]
17. Successful Use of Cyclosporin A for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Three Children. St John J; Ratushny V; Liu KJ; Bach DQ; Badri O; Gracey LE; Ho AW; Raff AB; Sugai DY; Schalock P; Kroshinsky D Pediatr Dermatol; 2017 Sep; 34(5):540-546. PubMed ID: 28884910 [TBL] [Abstract][Full Text] [Related]
18. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Tan SK; Tay YK Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108 [TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome. Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483 [TBL] [Abstract][Full Text] [Related]
20. Cyclosporine in SJS/TEN management: a brief review. Shokeen D Cutis; 2016 Mar; 97(3):E17-8. PubMed ID: 27023091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]